Teva Pharmaceutical Industries Ltd. (TEVA) Rating Reiterated by Maxim Group
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)‘s stock had its “buy” rating reissued by analysts at Maxim Group in a report issued on Friday. They presently have a $72.00 target price on the stock. Maxim Group’s target price would indicate a potential upside of 62.60% from the stock’s current price.
Several other brokerages also recently issued reports on TEVA. Mizuho reiterated a “buy” rating and set a $70.00 price target (down previously from $75.00) on shares of Teva Pharmaceutical Industries in a research report on Friday, August 5th. Goldman Sachs Group Inc. cut Teva Pharmaceutical Industries from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $70.00 to $60.00 in a report on Friday, July 15th. Guggenheim reissued a “buy” rating and set a $80.00 price objective on shares of Teva Pharmaceutical Industries in a report on Monday, August 15th. Leerink Swann reissued an “outperform” rating and set a $66.00 price objective on shares of Teva Pharmaceutical Industries in a report on Tuesday, August 16th. Finally, Jefferies Group dropped their price objective on Teva Pharmaceutical Industries from $72.00 to $69.00 and set a “buy” rating for the company in a report on Thursday, July 14th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, twenty have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $67.06.
Shares of Teva Pharmaceutical Industries (NYSE:TEVA) opened at 44.28 on Friday. The company’s 50 day moving average is $49.11 and its 200 day moving average is $52.25. The firm has a market capitalization of $40.47 billion, a PE ratio of 29.58 and a beta of 0.74. Teva Pharmaceutical Industries has a 12-month low of $43.80 and a 12-month high of $66.55.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/14/teva-pharmaceutical-industries-ltd-teva-rating-reiterated-by-maxim-group.html
Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Thursday, August 4th. The company reported $1.25 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.20 by $0.05. The business had revenue of $5 billion for the quarter, compared to the consensus estimate of $4.86 billion. Teva Pharmaceutical Industries had a net margin of 7.56% and a return on equity of 17.77%. The firm’s quarterly revenue was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.43 EPS. On average, analysts forecast that Teva Pharmaceutical Industries will post $5.24 earnings per share for the current year.
A number of large investors have recently bought and sold shares of TEVA. PGGM Investments boosted its stake in Teva Pharmaceutical Industries by 64.7% in the second quarter. PGGM Investments now owns 1,344,928 shares of the company’s stock worth $67,556,000 after buying an additional 528,470 shares during the period. Psagot Investment House Ltd. boosted its stake in Teva Pharmaceutical Industries by 81.9% in the second quarter. Psagot Investment House Ltd. now owns 1,070,005 shares of the company’s stock worth $53,746,000 after buying an additional 481,820 shares during the period. Deprince Race & Zollo Inc. boosted its stake in Teva Pharmaceutical Industries by 614.8% in the second quarter. Deprince Race & Zollo Inc. now owns 566,084 shares of the company’s stock worth $28,434,000 after buying an additional 486,894 shares during the period. RNC Capital Management LLC boosted its stake in Teva Pharmaceutical Industries by 384.5% in the second quarter. RNC Capital Management LLC now owns 392,970 shares of the company’s stock worth $19,739,000 after buying an additional 311,856 shares during the period. Finally, Panagora Asset Management Inc. boosted its stake in Teva Pharmaceutical Industries by 216.5% in the first quarter. Panagora Asset Management Inc. now owns 702,480 shares of the company’s stock worth $37,590,000 after buying an additional 480,509 shares during the period. Institutional investors and hedge funds own 63.35% of the company’s stock.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.
Receive News & Ratings for Teva Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.